India’s second-largest drugmaker Dr. Reddy’s Laboratories Ltd. said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its US business.
The deal is among Dr. Reddy’s biggest acquisitions, and comes at a time when the company has been facing slowing growth in the US, its largest market, due to regulatory troubles and fewer new drug approvals. Some formerly lucrative emerging markets have also taken a hit over the past year, and caused the company’s March quarter profit to slump 86 percent.
The drugs Dr. Reddy’s is buying are being divested by Israel-based Teva, the world’s largest maker of generic drugs, to win US antitrust clearance for its $40.5 billion acquisition of Allergan’s generic drugs portfolio. The sale to Dr. Reddy’s puts Teva a step closer to closing the Allergan deal.
The deal consists of generic drugs awaiting US approval, and some that are already on the market, including “complex generic products across diverse dosage forms,” Dr. Reddy’s said in a statement.
The branded versions of drugs under the deal had US sales of about $3.5 billion in the year to April 2016, the company said, citing health care research firm IMS Health.
Dr. Reddy’s said it plans to finance the deal with cash on hand and available borrowings under existing credit facilities.